This finding suggests that the PVP-I strongly inhibited inflammation signaling through NF-κB related molecule, such as IL-1β, and PVP-I may be used as a possible therapeutic remedy in CRS, especially non-eosinophilic CRS. This evidence concerns the gene NFKB1 and congenital rubella syndrome.